Supreme Court Imposes Stricter Patent Infringement Standards for Generic Pharmaceutical Manufacturers

In a unanimous decision in *Hikma v. Amarin*, the U.S. Supreme Court has tightened the legal standards for patent infringement liability against generic drugmakers. The ruling requires allegations of affirmative actions or statements designed to encourage infringement, rather than merely statements that could stimulate infringing conduct, potentially accelerating generic drug entry and lowering medication costs.